Biotech bears are maul­ing stocks as 2022 opens on a bleak note for in­vestors

As the first month of 2022 draws to a close, one thing seems to be on every­one’s mind in the bio­phar­ma world: a bur­geon­ing bear mar­ket.

While in­fla­tion and sup­ply chain is­sues have sent the Dow Jones and S&P 500 tum­bling — and the Nas­daq en­ter­ing cor­rec­tion ter­ri­to­ry — in re­cent weeks, few sec­tors have been hit as hard as biotech. The Nas­daq biotech­nol­o­gy in­dex and the XBI, two promi­nent barom­e­ters of pub­lic biotech per­for­mances, are down 15% and 20% since the start of the year, re­spec­tive­ly, out­pac­ing each of the three ma­jor US in­dices’ down­swings as of Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER